These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 32100597)
1. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
3. Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment. Jin H; Jin M; Lim CH; Choi JY; Kim SJ; Lee KH Front Oncol; 2023; 13():1186311. PubMed ID: 37384292 [TBL] [Abstract][Full Text] [Related]
4. [ Xu HQ; Song LJ; Ding CY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047 [TBL] [Abstract][Full Text] [Related]
5. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879 [TBL] [Abstract][Full Text] [Related]
6. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [ Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227 [TBL] [Abstract][Full Text] [Related]
7. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of Geng H; Lian K; Zhang W Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089 [TBL] [Abstract][Full Text] [Related]
9. Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma. So H; Lee H; Hyun SH; Cho YS; Moon SH; Choi JY; Lee KH Front Oncol; 2023; 13():1283582. PubMed ID: 38023238 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Values of Baseline Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229 [TBL] [Abstract][Full Text] [Related]
11. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916 [TBL] [Abstract][Full Text] [Related]
12. Metabolic tumor burden on baseline Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis. Guo B; Tan X; Ke Q; Cen H PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203 [TBL] [Abstract][Full Text] [Related]
15. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV Zhang YY; Song L; Zhao MX; Hu K Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111 [TBL] [Abstract][Full Text] [Related]
16. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome. Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989 [TBL] [Abstract][Full Text] [Related]
17. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T; Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452 [TBL] [Abstract][Full Text] [Related]
18. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial. Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535 [TBL] [Abstract][Full Text] [Related]
19. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma. Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of total metabolic tumour volume and therapy-response assessment by [ Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]